Medicaid spent billions more in 2016 than the year before on decades-old prescription drugs, including many generics, a Kaiser Health News data analysis shows.
Hospital use of two popular heart medicines, nitroprusside and isoproterenol, dramatically dropped after the prices for both soared.
Some drug courts offer participants a full range of evidence-based treatment, including medication-assisted treatment. Others don’t allow addiction medications at all. And some permit just one: Vivitrol.
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
KHN examines the role of PBMs in the prescription drug-pricing pipeline.
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
The controversial 340B drug discount program for hospitals came under fire at a congressional hearing.
Report by CDC researchers finds a steady fall in opioid use in recent years, but the rates are still three times higher than in 1999.
La gabapentina se utiliza para tratar afecciones de los nervios, pero la están usando cada vez más adictos a opioides. Es la quinta droga más recetada del país.
Gabapentin, prescribed for epilepsy and nerve damage, is touted by federal health officials as an alternative to opioids for patients. But some are now abusing the drug.
Among hurdles: Older adults may have multiple illnesses that could complicate research or they might be unable to manage the commute.
As we get older, it helps to tickle the noggin’ with trivia. Here’s a pop quiz to see what you have learned as a regular reader of Kaiser Health News.
A study finds that nearly 19 percent of people with mental illnesses use prescription drugs, while only 5 percent of other people do.
Documents examined by Kaiser Health News shed light on the workings of the Trump administration’s “Drug Pricing and Innovation Working Group.”
This year’s American Diabetes Association scientific meeting came with a hefty price — a policy of no photography and limits on social media. That did not go over well on Twitter.
Muchas veces los pacientes con cáncer no reciben respuestas adecuadas a preguntas críticas, entre ellas, la más crucial y universal de todas.
Due to poor doctor-patient communication, most people with advanced cancer don’t know enough about their disease to make vital decisions.
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
With the cost of medications up 300 percent in the past decade, supporters see this as a first step to rein in prices.